You are here

P&T September 2019

Features

House Democrats have been loudly proclaiming their intention to pass legislation that would rein in drug-price increases. But when it comes to actually passing  significant bills, reality has not matched rhetoric.

Carbapenems are a primary treatment for infections from multidrug-resistant bacterial pathogens. To maintain their efficacy and control the emergence of further resistance, breakpoints that correspond to recommended doses with appropriate PK/PD target attainment are paramount.

The exact mechanism of a tramadol–warfarin interaction has not been fully determined. The authors present a case study that illustrates the risks.

Continuous glucose monitoring offers patients with diabetes a new option for monitoring their glucose levels on a regular basis, without the need for perpetual finger-sticks and myriad supplies.

Self-monitoring of blood glucose alone is not a good predictor of HbA1c goal  attainment. Health plans might benefit from formulary restrictions to provide more cost-effective care, without negatively impacting glycemic control. And by using  targeted interventions, healthcare providers could help maximize SMBG’s clinical benefit for patients who receive test strips. 

Departments

Medication Errors

We present technology enhancements that support the safe use of U-500 insulin.

Prescription: Washington

The legal tactics that drug manufacturers use to extend drug patents may be the big-gest impediment to lowering drug prices and to Congress acting on pricing. Until now, that is.

Alpelisib (Piqray) for HR-positive/HER2-negative, PIK3CA-mutated, advanced/metastatic breast cancer; polatuzumab vedotin-piiq (Polivy) for diffuse large B-cell lymphoma; and eculizumab (Soliris) for neuromyelitis optica spectrum disorder.